Lantern Pharma (LTRN) Market Capitalization (2020 - 2026)

Lantern Pharma (LTRN) has reported Market Capitalization for 7 consecutive years, with $53.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 56.12% year-over-year to $53.2 million; the trailing twelve-month figure through Jun 2026 stood at $53.2 million (up 56.12% YoY), and the FY2025 full-year result was $34.1 million, down 0.88% from the prior year.
• Market Capitalization grew to $53.2 million in Q2 2026 per LTRN's latest filing, from $15.4 million in the prior quarter.
• Across five years, Market Capitalization topped out at $94.7 million in Q1 2024 and bottomed at $15.4 million in Q1 2026.
• Historically, Market Capitalization has averaged $49.7 million across 5 years, with a median of $49.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Market Capitalization slumped 62.13% in 2022, then soared 80.55% in 2024.
• Over 5 years, Market Capitalization stood at $65.6 million in 2022, then plunged by 30.03% to $45.9 million in 2023, then retreated by 25.03% to $34.4 million in 2024, then retreated by 0.88% to $34.1 million in 2025, then surged by 56.02% to $53.2 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $53.2 million, $15.4 million, and $34.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.